• Drug Response Metrics in Cancer In Vitro

  2026-08-07

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly substituted readouts capture different relationships between growth inhibition and cell killing. The work provides a practical framework for interpreting anticancer drug responses and for designing experiments that separate cytostatic effects from cytotoxicity.

• SCH772984 HCl: ERK1/2 Inhibitor Workflows in Cancer & Stem C

  2026-08-07

  SCH772984 HCl sets the benchmark for selective ERK1/2 inhibition in both cancer and stem cell research, enabling high-precision dissection of MAPK signaling and telomerase regulation. This guide bridges protocol setup, advanced applications, and expert troubleshooting for reproducible, high-impact results.

• Substance P in Applied Pain and Inflammation Research Workfl

  2026-08-06

  Substance P, a hallmark tachykinin neuropeptide, enables precise modeling of pain, inflammation, and neuroimmune signaling in the lab. This guide details advanced workflows, troubleshooting, and protocol refinements that leverage APExBIO’s high-purity Substance P for reproducible, data-driven outcomes.

• Optimizing ERK1/2 Inhibition Workflows with GDC-0994

  2026-08-06

  GDC-0994 is transforming ERK1/2 pathway studies, enabling precise modulation of tumor and liver models where MAP kinase signaling drives pathology. This guide details actionable protocols, cross-validates recent mechanistic breakthroughs, and delivers troubleshooting insights to maximize reproducibility and impact in translational research.

• BFH772 (VEGFR2 inhibitor): Technical Protocols and Workflow

  2026-08-05

  BFH772 is a highly selective VEGFR2 inhibitor designed for precise inhibition of VEGFR2-driven angiogenesis, particularly in tumor research settings. It is optimal for protocols requiring high kinase selectivity and compatibility with organic solvents but should not be used in workflows needing water solubility or broad-spectrum kinase inhibition.

• SCUBE3 Antibody Targeting Suppresses Oncogenic and Immune Ev

  2026-08-05

  This study identifies secretory protein SCUBE3 as a pivotal driver of therapy resistance, oncogenic signaling, and immune evasion in multiple cancer models, and demonstrates that antibody-mediated targeting of SCUBE3 profoundly suppresses tumor progression. The findings suggest that neutralizing SCUBE3 could represent a mechanistically distinct and promising strategy for pan-cancer treatment.

• Practical Guidance for Using AZD8055 as an mTOR Inhibitor

  2026-08-04

  AZD8055 is a potent, selective mTOR inhibitor enabling robust dissection of mTORC1 and mTORC2 signaling in preclinical cancer and metabolic research. It is unsuitable for studies prioritizing clinical efficacy endpoints but is well-suited for experiments demanding precise pathway inhibition. Proper solubilization, storage, and workflow discipline are critical for reproducible results.

• Torin2 Redefines mTOR Inhibition: Apoptosis Beyond Transcrip

  2026-08-04

  Discover how Torin2, a next-generation mTOR inhibitor, reveals new apoptotic mechanisms independent of transcriptional loss. This article provides a deep dive into Torin2’s selectivity and translational impact for cancer research.

• Nur77 Phase Separation Drives XS561-Induced Apoptosis in Can

  2026-08-03

  This study uncovers how the small molecule XS561 induces apoptosis in tumor cells by promoting phase separation of the orphan nuclear receptor Nur77 and its condensate formation with Bcl-2 at mitochondria. The findings provide mechanistic insights into Nur77/Bcl-2 signaling and highlight phase separation as a regulatory principle in apoptosis, with implications for targeted cancer therapies.

• Erastin Overcomes ABCB1-Mediated Docetaxel Resistance in Ova

  2026-08-03

  This study demonstrates that Erastin, a ferroptosis inducer, can reverse ABCB1-mediated resistance to docetaxel in ovarian cancer cells by inhibiting drug efflux without altering ABCB1 expression. The findings suggest a promising combination strategy to enhance chemotherapy efficacy in multidrug-resistant ovarian cancer.

• Brinzolamide Nanoemulsions: Permeation, Safety, and the Role

  2026-08-02

  This study developed and evaluated brinzolamide-loaded nanoemulsions for ocular drug delivery, demonstrating enhanced corneal permeation and low irritancy compared to conventional suspensions. The findings highlight the importance of excipient selection, with Triacetin emerging as a safe and effective oil phase component for ophthalmic formulations.

• Angiotensin III (human, mouse): Advanced Mechanistic Insight

  2026-08-01

  Explore the multifaceted role of Angiotensin III in the renin-angiotensin-aldosterone system and its emerging relevance to viral entry mechanisms. This deep-dive article offers fresh mechanistic insights and protocol guidance beyond existing resources.

• Applied Use of AT13387: Optimizing Hsp90 Inhibitor Workflows

  2026-07-31

  AT13387, a next-generation Hsp90 inhibitor, combines nanomolar potency with oral bioavailability, empowering cancer biology researchers to dissect apoptosis and cell cycle regulation with unprecedented precision. This guide translates bench data and recent mechanistic insights into actionable protocols and troubleshooting strategies, unlocking the full experimental potential of APExBIO's AT13387.

• Butylhydroxyanisole (BHA): Advanced Antioxidant Protocols an

  2026-07-31

  Discover the scientific foundations and nuanced protocols for Butylated Hydroxyanisole (BHA) in oxidative stress research. This article delves into BHA's mechanism, reference-backed assay design, and practical insights not found in standard guides.

• Acetylcholine Chloride: Decoding Cholinergic Pathways in Epi

  2026-07-30

  Explore how Acetylcholine Chloride advances the understanding of acetylcholine neurotransmitter signaling in epilepsy and gut-brain research. This article uniquely dissects mechanistic innovations and practical protocols, setting a new standard for translational neuroscience.

15751 records 1/1051 page Next 12345 下5页 Last page